CN115708530B - Pregnant and lying-in woman formula milk powder capable of promoting digestion comfort and stabilizing blood sugar and preparation method thereof - Google Patents
Pregnant and lying-in woman formula milk powder capable of promoting digestion comfort and stabilizing blood sugar and preparation method thereof Download PDFInfo
- Publication number
- CN115708530B CN115708530B CN202211429648.1A CN202211429648A CN115708530B CN 115708530 B CN115708530 B CN 115708530B CN 202211429648 A CN202211429648 A CN 202211429648A CN 115708530 B CN115708530 B CN 115708530B
- Authority
- CN
- China
- Prior art keywords
- powder
- milk
- parts
- pregnant
- lying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000843 powder Substances 0.000 title claims abstract description 119
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 53
- 239000008280 blood Substances 0.000 title claims abstract description 34
- 210000004369 blood Anatomy 0.000 title claims abstract description 33
- 230000029087 digestion Effects 0.000 title claims abstract description 31
- 235000000346 sugar Nutrition 0.000 title claims abstract description 28
- 230000000087 stabilizing effect Effects 0.000 title claims abstract description 25
- 230000001737 promoting effect Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 235000013336 milk Nutrition 0.000 claims abstract description 54
- 239000008267 milk Substances 0.000 claims abstract description 54
- 210000004080 milk Anatomy 0.000 claims abstract description 54
- 150000001875 compounds Chemical class 0.000 claims abstract description 47
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 32
- 235000016709 nutrition Nutrition 0.000 claims abstract description 31
- 230000035764 nutrition Effects 0.000 claims abstract description 31
- 239000003623 enhancer Substances 0.000 claims abstract description 29
- 239000006041 probiotic Substances 0.000 claims abstract description 22
- 235000018291 probiotics Nutrition 0.000 claims abstract description 22
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims abstract description 17
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 16
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 15
- 239000008101 lactose Substances 0.000 claims abstract description 15
- 230000000529 probiotic effect Effects 0.000 claims abstract description 15
- 239000004519 grease Substances 0.000 claims abstract description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 14
- 239000011707 mineral Substances 0.000 claims abstract description 12
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 11
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 11
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 11
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 11
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 11
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 10
- 239000000047 product Substances 0.000 claims description 27
- 235000020185 raw untreated milk Nutrition 0.000 claims description 24
- 229940088594 vitamin Drugs 0.000 claims description 16
- 229930003231 vitamin Natural products 0.000 claims description 16
- 235000013343 vitamin Nutrition 0.000 claims description 16
- 239000011782 vitamin Substances 0.000 claims description 16
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 12
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 235000010755 mineral Nutrition 0.000 claims description 11
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 10
- 241000283690 Bos taurus Species 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 239000002131 composite material Substances 0.000 claims description 8
- 239000011578 levomefolic acid Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 238000005238 degreasing Methods 0.000 claims description 7
- 239000004222 ferrous gluconate Substances 0.000 claims description 7
- 235000013924 ferrous gluconate Nutrition 0.000 claims description 7
- 229960001645 ferrous gluconate Drugs 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims description 7
- 239000011670 zinc gluconate Substances 0.000 claims description 7
- 229960000306 zinc gluconate Drugs 0.000 claims description 7
- 235000011478 zinc gluconate Nutrition 0.000 claims description 7
- 229930003316 Vitamin D Natural products 0.000 claims description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 6
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 235000013365 dairy product Nutrition 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 235000020200 pasteurised milk Nutrition 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- 235000019166 vitamin D Nutrition 0.000 claims description 6
- 239000011710 vitamin D Substances 0.000 claims description 6
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 6
- 229940046008 vitamin d Drugs 0.000 claims description 6
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 5
- 229960001231 choline Drugs 0.000 claims description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 5
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 5
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 230000008774 maternal effect Effects 0.000 claims description 5
- 239000011265 semifinished product Substances 0.000 claims description 5
- 239000011781 sodium selenite Substances 0.000 claims description 5
- 235000015921 sodium selenite Nutrition 0.000 claims description 5
- 229960001471 sodium selenite Drugs 0.000 claims description 5
- 229960003080 taurine Drugs 0.000 claims description 5
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 241001608472 Bifidobacterium longum Species 0.000 claims description 4
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 4
- 235000020247 cow milk Nutrition 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000009395 breeding Methods 0.000 claims description 3
- 230000001488 breeding effect Effects 0.000 claims description 3
- -1 compound vitamin Chemical class 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000009928 pasteurization Methods 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract description 28
- 235000015097 nutrients Nutrition 0.000 abstract description 16
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract description 14
- 235000019152 folic acid Nutrition 0.000 abstract description 14
- 239000011724 folic acid Substances 0.000 abstract description 14
- 229960000304 folic acid Drugs 0.000 abstract description 14
- 102000007544 Whey Proteins Human genes 0.000 abstract description 12
- 108010046377 Whey Proteins Proteins 0.000 abstract description 12
- 235000021119 whey protein Nutrition 0.000 abstract description 12
- 238000010521 absorption reaction Methods 0.000 abstract description 8
- 239000006071 cream Substances 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 239000005018 casein Substances 0.000 abstract description 4
- 230000003871 intestinal function Effects 0.000 abstract description 4
- 208000004104 gestational diabetes Diseases 0.000 abstract description 3
- 238000009700 powder processing Methods 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 description 19
- 150000003722 vitamin derivatives Chemical class 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- 102000011632 Caseins Human genes 0.000 description 9
- 108010076119 Caseins Proteins 0.000 description 9
- 102000004407 Lactalbumin Human genes 0.000 description 9
- 108090000942 Lactalbumin Proteins 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 235000021247 β-casein Nutrition 0.000 description 8
- 235000021241 α-lactalbumin Nutrition 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 235000021552 granulated sugar Nutrition 0.000 description 3
- 235000015816 nutrient absorption Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229910001297 Zn alloy Inorganic materials 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037180 bone health Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 2
- 235000007635 levomefolic acid Nutrition 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 101150019913 MTHFR gene Proteins 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- 208000031964 Other metabolic disease Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229940091251 zinc supplement Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to pregnant and lying-in women formula milk powder for promoting digestion comfort and stabilizing blood sugar and a preparation method thereof, and belongs to the technical field of milk powder processing. In order to solve the problem that the prior pregnant and lying-in woman milk powder has incomplete consideration on nutrient absorbability and product comfortableness, the invention provides the pregnant and lying-in woman formula milk powder for promoting digestion comfortableness and stabilizing blood sugar, which comprises the components of A2 type skim milk, lactose, whey protein powder, cream, galacto-oligosaccharide, fructo-oligosaccharide, phospholipid, compound nutrition enhancer, docosahexaenoic acid grease powder, N-acetylneuraminic acid and compound probiotic powder. The nutrient such as A2β -casein, organic minerals, active folic acid and the like in the formula milk powder for pregnant and lying-in women provided by the invention has the characteristics of strong absorbability and the like, can assist the pregnant and lying-in women to reasonably absorb the required nutrient substances, and is particularly suitable for being eaten by pregnant women, pregnant women and postpartum women suffering from gestational diabetes mellitus, and having weak intestinal functions and high requirements on digestion and absorption of the nutrient substances.
Description
Technical Field
The invention belongs to the technical field of milk powder processing, and particularly relates to pregnant and lying-in woman formula milk powder capable of promoting digestion comfort and stabilizing blood sugar and a preparation method thereof.
Background
The nutrition supplement in pregnancy and lactation is directly related to the health of the mother and child.
Although the pregnant and lying-in women milk powder products on the market at present consider the enhanced nutrients, the problems of incomplete consideration of the absorbability of the nutrients and the comfort of the products still exist due to weak intestinal functions and poor digestion and absorption capacity of pregnant women; inorganic mineral salts and synthetic folic acid products are most available in the market, organic mineral salts and natural folic acid products are less, and targeted reinforcement of intake and absorbability is not considered; although some products are marked without sugar, other raw materials and auxiliary materials in the formula can also influence the blood sugar during pregnancy, and the pregnant and lying-in women with stable blood sugar is purposefully considered to have fewer products, so that the pregnant and lying-in women formula milk powder with good nutrient absorption and product comfort is urgently needed to be developed.
Disclosure of Invention
The invention provides pregnant and lying-in woman formula milk powder capable of promoting digestion comfort and stabilizing blood sugar and a preparation method thereof, and aims to solve the problem that the existing pregnant and lying-in woman milk powder is not comprehensive in consideration of nutrient absorbability and product comfort.
The technical scheme of the invention is as follows:
The pregnant and lying-in woman formula milk powder for promoting digestion comfort and stabilizing blood sugar comprises the following raw material components in parts by weight: 50 to 85 parts of A2 type defatted raw milk, 0 to 30 parts of lactose, 0 to 4 parts of whey protein powder, 0 to 25 parts of cream, 1 to 6 parts of galacto-oligosaccharide, 1 to 6 parts of fructo-oligosaccharide, 0.2 to 0.6 part of phospholipid, 0.6 to 1.0 part of compound nutrition enhancer, 0.5 to 1.5 parts of docosahexaenoic acid grease powder, 0.03 to 0.2 part of N-acetylneuraminic acid and 0.04 to 0.08 part of compound probiotics powder.
Further, the material comprises the following raw material components in parts by weight: 60 to 80 parts of A2 type defatted raw milk, 0 to 25 parts of lactose, 0 to 2.5 parts of whey protein powder, 0 to 20 parts of cream, 2 to 3.5 parts of galacto-oligosaccharide, 2 to 5.5 parts of fructo-oligosaccharide, 0.2 to 0.5 part of phospholipid, 0.6 to 0.9 part of compound nutrition enhancer, 0.8 to 1.5 parts of docosahexaenoic acid oil fat powder, 0.05 to 0.18 part of N-acetylneuraminic acid and 0.05 to 0.06 part of compound probiotics powder.
Further, the material comprises the following raw material components in parts by weight: 65 to 80 parts of A2 type defatted raw milk, 0 to 20 parts of lactose, 0 to 2 parts of whey protein powder, 0 to 18 parts of cream, 2.5 to 3.5 parts of galacto-oligosaccharide, 3 to 5.5 parts of fructo-oligosaccharide, 0.3 to 0.5 part of phospholipid, 0.7 to 0.9 part of compound nutrition enhancer, 0.8 to 1.2 parts of docosahexaenoic acid oil fat powder, 0.05 to 0.18 part of N-acetylneuraminic acid and 0.05 to 0.06 part of compound probiotics powder.
Further, the compound nutrition enhancer comprises the following components in parts by weight: 60-80 parts of compound vitamins, 20-40 parts of compound minerals and 1-5 parts of lactose.
Further, the compound vitamin comprises the following components in percentage by weight: 0.55 to 0.85 percent of vitamin A, 0.4 to 0.5 percent of vitamin D, 3.5 to 4.8 percent of vitamin E, 3.00 to 4.00 percent of vitamin K 2, 0.10 to 0.15 percent of vitamin B 1, 1.00 to 1.50 percent of vitamin B 2, 3.00 to 3.80 percent of vitamin B 6, 0.05 to 0.15 percent of 6S-5-methyltetrahydrofolate calcium, 0.02 to 0.08 percent of vitamin B 12, 19.00 to 22.00 percent of vitamin C, 20.10 to 28.50 percent of choline, 4.00 to 5.50 percent of L-carnitine, 4.20 to 5.50 percent of taurine and the balance of lactose.
Further, the compound mineral comprises the following components in percentage by weight: 15.00 to 25.00 percent of ferrous gluconate, 6.50 to 8.70 percent of zinc gluconate, 0.75 to 1.25 percent of sodium selenite and the balance of lactose.
Further, the composite probiotic powder is composed of at least two of bifidobacterium animalis subspecies Bb-12, bifidobacterium animalis subspecies HN019, bifidobacterium animalis subspecies Bi-07 and bifidobacterium longum subspecies BB536 according to any proportion.
A preparation method of pregnant and lying-in woman formula milk powder for promoting digestion comfort and stabilizing blood sugar comprises the following steps:
step one, screening and collecting A2 raw cow milk:
selecting pure breed A2 dairy cows and carrying out clustered breeding and cultivation and collecting A2 raw dairy cows by carrying out gene identification screening on large-scale pasture dairy cows;
Step two, degreasing the raw milk of the A2:
filtering, cooling and storing the A2 raw milk obtained in the step one, degreasing to obtain skimmed milk, homogenizing the skimmed milk after degerming and separating, and then pasteurizing to obtain pasteurized milk, and cooling and storing;
Step three, batching:
Adding other auxiliary materials except the docosahexaenoic acid grease powder, the N-acetylneuraminic acid, the compound nutrition enhancer and the compound probiotic powder into a vacuum mixer according to the formula weight parts to be mixed; dissolving the compound nutrition enhancer according to the water-powder mass ratio required by the process at the dissolving temperature, adding the dissolved compound nutrition enhancer into a vacuum mixer, and mixing the dissolved compound nutrition enhancer with other auxiliary materials and pasteurized milk obtained in the step two to obtain the prepared milk;
step four, preparing a semi-finished product of milk powder:
homogenizing the prepared milk obtained in the step three, removing most of water in the prepared milk through vacuum sterilization and concentration to obtain concentrated milk, and performing spray drying and fluidized bed cooling on the obtained concentrated milk to obtain a milk powder semi-finished product;
Step five, preparing a milk powder finished product:
premixing the docosahexaenoic acid grease powder, the N-acetylneuraminic acid and the compound probiotic powder with part of the semi-finished milk powder obtained in the step four according to the formula requirement in parts by weight to obtain a premix, fully mixing the rest semi-finished milk powder with the premix, and packaging to obtain the finished pregnant and lying-in woman formula milk powder.
Further, the impurity degree of the A2 raw milk obtained by filtering in the second step is less than 0.25ppm; step two, the pasteurization temperature is 80-85 ℃ and the sterilization time is 15s; in the third step, the mass ratio of water to powder is not lower than 8:1 when the compound nutrition enhancer is dissolved, and the dissolution temperature is 30-50 ℃.
Further, the homogenizing pressure in the fourth step is 160-210 bar, the sterilizing temperature of vacuum sterilization and concentration is 85-98 ℃, the moisture of the prepared milk removed by concentration is 60%, and the density of the obtained concentrated milk is 1100-1200 kg/m 3; the high-pressure pump pressure of the spray drying is 150-250 bar, the air inlet temperature is 160-200 ℃, the air exhaust temperature is 65-90 ℃, and the fluidized bed cooling is to cool the finished milk powder to 10-30 ℃; and fifthly, premixing for 5-10 min, wherein the mixing time is 5-10 min, the oxygen content in the package of the packaged bagged product is lower than 2.5%, and the oxygen content in the package of the canned product is lower than 5.0%.
The invention has the beneficial effects that:
The formula milk powder for pregnant and lying-in women provided by the invention has the effects of improving digestion and absorption functions of the pregnant and lying-in women and improving gastrointestinal comfort of the product. Aiming at the physiological characteristics of gastrointestinal tract digestion characteristics of pregnant and lying-in women, the raw material is preferably pure A2 beta-casein organic raw cow milk, and the raw material and whey protein (containing alpha-lactalbumin) are subjected to double-protein combination, so that the problem of weak gastrointestinal tract function of pregnant and lying-in women is improved on the basis of meeting the nutrient requirements of the pregnant and lying-in women, and the subsequent nutrient absorption is facilitated.
The formula milk powder for pregnant and lying-in women provided by the invention has the effect of enhancing nutrient absorption. The invention preferably adds the active folic acid, the organic mineral salt and the vitamin K 2, the active folic acid has better absorptivity, no metabolic step is needed, the addition is reasonable, and the kidney burden is small; the mineral sources preferably adopt organic mineral salts zinc gluconate and ferrous gluconate as ferric sulfate and zinc sulfate, so that the absorption effect is better; vitamin D and vitamin K 2 act synergistically to maintain bone health.
The formula milk powder for pregnant and lying-in women provided by the invention has the effect of stabilizing the blood sugar level of the pregnant and lying-in women. According to the invention, oligosaccharide and the like are added, white granulated sugar and the like are not added, the GI value is controlled to be less than or equal to 55, the GL value is less than 10, the food with low GI and low GL is provided, and meanwhile, the vitamin K 2 which is an important nutrition factor for controlling and preventing diabetes is added, so that the blood sugar level of pregnant and lying-in women can be stabilized.
The nutrient such as A2β -casein, organic minerals, active folic acid and the like in the formula milk powder for pregnant and lying-in women provided by the invention has the characteristics of strong absorbability and the like, can assist the pregnant and lying-in women to reasonably absorb the required nutrient substances, and is particularly suitable for being eaten by pregnant women, pregnant women and postpartum women suffering from gestational diabetes mellitus, and having weak intestinal functions and high requirements on digestion and absorption of the nutrient substances.
Drawings
Fig. 1 is a graph of the test blood glucose response of the food test for 12 subjects in example 4.
Detailed Description
The following embodiments are used for further illustrating the technical scheme of the present invention, but not limited thereto, and all modifications and equivalents of the technical scheme of the present invention are included in the scope of the present invention without departing from the spirit and scope of the technical scheme of the present invention. The process equipment or apparatus not specifically noted in the following examples are all conventional equipment or apparatus in the art, and the raw materials and the like used in the examples of the present invention are commercially available unless otherwise specified; unless specifically indicated, the technical means used in the embodiments of the present invention are conventional means well known to those skilled in the art.
Example 1
The embodiment provides pregnant and lying-in woman formula milk powder capable of promoting digestion comfort and stabilizing blood sugar and a preparation method thereof.
The pregnant and lying-in woman formula milk powder for promoting digestion comfort and stabilizing blood sugar provided by the embodiment comprises the following raw material components in parts by weight:
79 parts of A2 type skim raw milk based on dry matter,
18 Parts of cream,
3.4 Parts of galacto-oligosaccharide,
5.4 Parts of fructo-oligosaccharide,
0.3 Part of phospholipid,
0.8 Part of compound nutrition enhancer,
0.9 Part of docosahexaenoic acid grease powder,
0.053 Part of N-acetylneuraminic acid,
0.05 Part of composite probiotic powder.
The compound nutrition enhancer of the embodiment comprises the following components in percentage by weight: vitamin A0.75%, vitamin D0.47%, vitamin E4.2%, vitamin K 2 3.64.64%, vitamin B 1 0.15.15%, vitamin B 2 1.35.35%, vitamin B 6 3.29.29%, 6S-5-methyltetrahydrofolate calcium 0.1%, vitamin B 12 0.04.04%, ferrous gluconate 18.75%, zinc gluconate 7.66%, sodium selenite 0.95%, vitamin C19.61%, choline 24.51%, L-carnitine 4.90%, taurine 4.90% and lactose in balance.
The composite probiotic powder of the embodiment consists of bifidobacterium animalis subspecies Bb-12, bifidobacterium animalis subspecies HN019 and the ratio of 5:1.
The preparation method of the pregnant and lying-in woman formula milk powder for promoting digestion comfort and stabilizing blood sugar provided by the embodiment comprises the following steps:
step one, screening and collecting A2 raw cow milk:
the method comprises the steps of screening large-scale pasture cows by gene identification, selecting pure A2 cows, carrying out clustered breeding and cultivation on the cows producing A2 type beta-casein, and collecting A2 raw milk; the content of the A2 type beta-casein in the raw milk is 0.9-2.5 percent, and each index and the inspection method are executed according to GB 193012010 national Standard raw milk for food safety;
Step two, degreasing the raw milk of the A2:
Filtering the A2 raw milk obtained in the step one, wherein the impurity degree of the obtained A2 raw milk is less than 0.25ppm, cooling and storing, degreasing by a degreasing separator to obtain the skimmed milk, homogenizing the obtained skimmed milk after degerming and separating, performing pasteurization at 82 ℃ for 15s to ensure that bacteria of the skimmed milk reach a specified range, obtaining pasteurized milk, and cooling and storing;
Step three, batching:
Adding the cream, the galacto-oligosaccharide and the fructo-oligosaccharide which meet the standard and the phospholipid into a vacuum mixer according to the weight parts required by the formula to be mixed; dissolving the compound nutrition enhancer in a special nutrient tank according to the water-powder mass ratio of 9:1 required by the process at the temperature of 40 ℃, adding the dissolved compound nutrition enhancer into a vacuum mixer, and mixing the dissolved compound nutrition enhancer with other auxiliary materials and pasteurized milk obtained in the step two to obtain the prepared milk;
step four, preparing a semi-finished product of milk powder:
homogenizing the prepared milk obtained in the step three, wherein the homogenizing pressure is 180bar, then removing 60% of water in the prepared milk through vacuum sterilization and concentration at 90 ℃ to obtain concentrated milk with the density of 1100kg/m 3, spray-drying the obtained concentrated milk, wherein the pressure of a high-pressure pump for spray-drying is 200bar, the air inlet temperature is 180 ℃, the air outlet temperature is 85 ℃, and then cooling the finished milk powder to 20 ℃ by fluidized bed cooling to obtain a semi-finished milk powder;
Step five, preparing a milk powder finished product:
Premixing docosahexaenoic acid grease powder, N-acetylneuraminic acid and compound probiotics powder with part of the semi-finished milk powder obtained in the fourth step for 10min according to the formula requirement weight part to obtain premix, fully mixing the rest semi-finished milk powder with the premix for 10min, and packaging to obtain the finished milk powder for pregnant and lying-in women. The oxygen content in the package of the packaged bagged product is lower than 2.5%, and the oxygen content in the package of the canned product is lower than 5.0%.
The key technical indexes obtained by the pregnant and lying-in women formula milk powder prepared in the embodiment are shown in table 1.
TABLE 1
Example 2
The embodiment provides pregnant and lying-in woman formula milk powder capable of promoting digestion comfort and stabilizing blood sugar and a preparation method thereof.
The pregnant and lying-in woman formula milk powder for promoting digestion comfort and stabilizing blood sugar provided by the embodiment comprises the following raw material components in parts by weight:
73 parts of A2 type skim raw milk calculated by dry matter,
15 Parts of lactose,
Whey protein powder 1 part,
3.4 Parts of galacto-oligosaccharide,
5.4 Parts of fructo-oligosaccharide,
0.3 Part of phospholipid,
0.8 Part of compound nutrition enhancer,
1.2 Parts of docosahexaenoic acid grease powder,
0.154 Part of N-acetylneuraminic acid,
0.05 Part of composite probiotic powder.
The compound nutrition enhancer of the embodiment comprises the following components in percentage by weight: vitamin A0.75%, vitamin D0.47%, vitamin E4.2%, vitamin K 2 3.64.64%, vitamin B 1 0.15.15%, vitamin B 2 1.35.35%, vitamin B 6 3.29.29%, 6S-5-methyltetrahydrofolate calcium 0.1%, vitamin B 12 0.04.04%, ferrous gluconate 18.75%, zinc gluconate 7.00%, sodium selenite 0.95%, vitamin C19.61%, choline 24.51%, L-carnitine 4.90%, taurine 4.90% and lactose in balance.
The composite probiotic powder of the embodiment consists of bifidobacterium animalis subspecies Bb-12 and bifidobacterium longum subspecies BB536 according to the ratio of 4:1.
The content of the A2 type beta-casein in the raw milk is 0.9 to 2.5 percent; the alpha-lactalbumin in the milk base is added in the form of whey protein powder, and the content of the alpha-lactalbumin in the whey protein powder is 30-70%.
The preparation method of the pregnant and lying-in women formula milk powder of the embodiment is the same as that of the embodiment 1, and the technical indexes obtained by the prepared pregnant and lying-in women formula milk powder are shown in table 2.
TABLE 2
| Nutrient project | Content (per 100 g milk powder) |
| A2 type beta-casein | 8.4g |
| Lactalbumin | 1.2g |
| Folic acid | 500μg |
| Vitamin K 2 | 35μg |
| Iron (Fe) | 15mg |
| Zinc alloy | 5mg |
| Probiotics | 1.5×109CFU |
| N-acetylneuraminic acid | 150mg |
| Dietary fiber | 6.2g |
Example 3
The embodiment provides pregnant and lying-in woman formula milk powder capable of promoting digestion comfort and stabilizing blood sugar and a preparation method thereof.
The pregnant and lying-in woman formula milk powder for promoting digestion comfort and stabilizing blood sugar provided by the embodiment comprises the following raw material components in parts by weight:
67 parts of A2 type defatted raw milk based on dry matter,
20 Parts of lactose,
Whey protein powder 2 parts,
3.4 Parts of galacto-oligosaccharide,
5.4 Parts of fructo-oligosaccharide,
0.3 Part of phospholipid,
0.8 Part of compound nutrition enhancer,
1 Part of docosahexaenoic acid grease powder,
0.12 Part of N-acetylneuraminic acid,
0.05 Part of composite probiotic powder.
The compound nutrition enhancer of the embodiment comprises the following components in percentage by weight: vitamin A0.75%, vitamin D0.47%, vitamin E4.2%, vitamin K 2 3.64.64%, vitamin B 1 0.15.15%, vitamin B 2 1.35.35%, vitamin B 6 3.29.29%, 6S-5-methyltetrahydrofolate calcium 0.13%, vitamin B 12 0.04.04%, ferrous gluconate 22.4%, zinc gluconate 7.00%, sodium selenite 0.95%, vitamin C19.61%, choline 24.51%, L-carnitine 4.90%, taurine 4.90% and lactose in balance.
The composite probiotic powder of the embodiment consists of bifidobacterium animalis subspecies Bb-12, bifidobacterium animalis subspecies HN019, bifidobacterium animalis subspecies Bi-07 and bifidobacterium longum subspecies BB536 according to equal proportion.
The content of the A2 type beta-casein in the raw milk is 0.9 to 2.5 percent; the alpha-lactalbumin in the milk base is added in the form of whey protein powder, and the content of the alpha-lactalbumin in the whey protein powder is 30-70%.
The preparation method of the pregnant and lying-in women formula milk powder of the embodiment is the same as that of the embodiment 1, and the technical indexes obtained by the prepared pregnant and lying-in women formula milk powder are shown in table 3.
TABLE 3 Table 3
| Nutrient project | Content (per 100 g milk powder) |
| A2 type beta-casein | 8.0g |
| Lactalbumin | 1.5g |
| Folic acid | 400μg |
| Vitamin K 2 | 35μg |
| Iron (Fe) | 18mg |
| Zinc alloy | 5mg |
| Probiotics | 1.5×109CFU |
| N-acetylneuraminic acid | 100mg |
| Dietary fiber | 6.2g |
Example 4
The embodiment performs test verification on the blood sugar stabilizing efficacy of the pregnant and lying-in women milk powder.
The test method comprises the following steps: human test methods according to WS/T652-2019 methods for determining glycemic index of foods.
12 Qualified volunteers are screened, the ages are 18-60 years, the body mass index is in the normal range of 18.5kg/m 2-24.0kg/m2, the volunteers can tolerate the fasting state for at least 10 hours, no history of diabetes, impaired glucose tolerance, other metabolic diseases, digestive system diseases and the like are avoided, no allergic and intolerance history is caused to products of the invention, and no nutrient supplement and any medicine affecting the glucose tolerance are taken in 3 months.
Performing test food measurement for 3 times, wherein each measurement interval exceeds 72 hours, the test food measurement of the food to be measured is arranged between two reference foods, and the regular work and rest of the subjects in the first three days are measured, so that the food is normally eaten; measuring the dinner of the previous day to avoid high dietary fiber and high confectionery, and starting fasted before 22:00; during the measurement, when the test is started after the test subject sits still for 10min on the morning, 2 fasting blood samples are collected at intervals of 5min, a reference food of glucose solution formed by dissolving 20g of glucose in 250mL of purified water at 45 ℃ is taken, and a test food of milk powder solution formed by dissolving the pregnant and lying-in women milk powder prepared in example 1 in 250mL of purified water at 45 ℃ is taken, wherein the blood samples are collected 15min, 30min, 45min, 60min, 90min and 120min after the start of the intake. After drawing a blood glucose response curve, calculating the GI value and the GL value of the product according to the following formula:
The calculation of the GI value of the food to be tested is shown in the formulas (1) and (2):
Gin—the GI value obtained from the subject individual;
n—the number of subjects who eventually included the calculation of the GI value of the food to be tested;
GI-GI value of food to be measured
The method for calculating the GL value of the food to be detected comprises the following steps:
GL＝C×GI/100
GL-blood glucose load value;
GI-the GI value of the food to be measured;
C-available carbohydrate content per unit mass of food in grams (g).
The test results of the 12 subjects are shown in Table 4.
TABLE 4 Table 4
According to the GI value results in Table 1, the available carbohydrate content per unit mass of food in the product of the invention was 46.8g; the test results show that the GI value is 16.64, the GL value is 7.79, and the GI is less than or equal to 55 and GL is less than 10 according to the food GI and GL grading judgment standard, so that the pregnant and lying-in woman milk powder prepared in the example 1 has the effect of stabilizing blood sugar.
Comparative example 1
This comparative example provides a formula which differs from example 1 only in that the raw milk is a non-organic A2 raw milk, the mineral source is an inorganic mineral, and white granulated sugar is added to the formula.
Specifically, the comparative formula milk powder comprises the following components in parts by weight:
57 parts of common raw milk calculated by dry matter,
22 Parts of whey protein powder,
10 Parts of maltodextrin,
4.5 Parts of white granulated sugar,
4.5 Parts of fructo-oligosaccharide,
1 Part of calcium carbonate,
0.6 Part of compound nutrition enhancer,
0.6 Part of docosahexaenoic acid grease powder.
The preparation method of the formula milk powder of the comparative example is the same as that of example 1.
Example 5
This example provides a follow-up evaluation of the digestive comfort of the maternal formula prepared in example 1 and the formula provided in comparative example 1.
30 Pregnant and parturient volunteers were recruited, the physical condition of the volunteers was recorded in detail prior to the trial, and all volunteers had no history of intestinal diseases, including gastric reflux, inflammatory bowel disease, no milk allergy symptoms, no use of drugs that might affect digestive function, etc.
The enrolled 30 volunteers were provided with both the product of comparative example 1 and the product of example 1, and were twice daily with 35g of milk powder supplemented with 200ml of water to prepare the formula of example 1 and comparative example 1, which was evaluated for comfort after a two month period and the results are shown in table 5.
TABLE 5
From the statistics of Table 5, it can be seen that, in the case that 27 volunteers had no abdominal distension, diarrhea and constipation in 30 volunteers, there was a significant improvement compared with the product of comparative example 1, in the period of 2 months when the comparative example product and the maternal formula of the present invention were taken together. The milk powder for pregnant and lying-in women, which is disclosed by the invention, is continuously taken, and the comfort of the volunteers of the pregnant and lying-in women to the product is obviously improved: symptoms affecting the comfort of the product such as abdominal distension, diarrhea and constipation are rarely generated.
The A2-beta casein contained in the pregnant and lying-in woman milk powder can achieve the aim of regulating gastrointestinal health, and can improve intestinal digestion comfort of female lactose intolerant patients; the alpha-lactalbumin and the oligosaccharide can synergistically promote the proliferation of bifidobacteria in the intestinal tract, improve the health of the intestinal tract and build a good intestinal environment; meanwhile, the alpha-lactalbumin has sites for combining divalent metal ions such as calcium, iron, zinc, manganese and the like, and the beta-casein is cooperated to promote the absorption of the metal ions such as calcium, zinc and the like. The iron and zinc supplement of the invention has higher solubility of ferrous gluconate than ferrous sulfate, and the bioavailability of zinc gluconate is higher than that of zinc sulfate, thus being more beneficial to the digestion and absorption of human bodies, particularly pregnant and lying-in women with weak gastrointestinal digestion function; vitamin K 2 can improve the sensitivity of insulin and has potential effect in preventing and/or treating diabetes, vitamin D can stimulate vitamin K 2 -dependent protein synthesis in calcium metabolism, and when the vitamin D is taken, the demand of human body for vitamin K 2 can be correspondingly increased, and the synergistic effect of vitamin D and vitamin K can maintain bone health. The synthesized folic acid is required to be metabolized in a human body by 4 steps and is converted into the 5-methyltetrahydrofolate with biological activity, and then the 5-methyltetrahydrofolate is absorbed by the human body, and according to statistics, more than 70% of people in China have MTHFR gene defects (risk of metabolic disorder of the synthesized folic acid), so that the risk is far from the pregnant and lying-in women, and the health of the pregnant and lying-in women is influenced, and researches show that if too much folic acid is added, a large amount of unabsorbed folic acid enters blood, the influence of the folic acid on the health exists for a long time, and the added 6S-5-methyltetrahydrofolate is not metabolized and is directly absorbed. The nutrient such as A2β -casein, organic minerals, active folic acid and the like in the formula milk powder for pregnant and lying-in women provided by the invention has the characteristics of strong absorbability and the like, can assist the pregnant and lying-in women to reasonably absorb the required nutrient substances, and is particularly suitable for being eaten by pregnant women, pregnant women and postpartum women suffering from gestational diabetes mellitus, and having weak intestinal functions and high requirements on digestion and absorption of the nutrient substances.
Claims (7)
1. The pregnant and lying-in woman formula milk powder for promoting digestion comfort and stabilizing blood sugar is characterized by comprising the following raw material components in parts by weight: 50-85 parts of A2 type defatted raw milk, 1-6 parts of galacto-oligosaccharide, 1-6 parts of fructo-oligosaccharide, 0.2-0.6 part of phospholipid, 0.6-1.0 part of compound nutrition enhancer, 0.5-1.5 parts of docosahexaenoic acid grease powder, 0.03-0.2 part of N-acetylneuraminic acid and 0.04-0.08 part of compound probiotic powder;
The compound nutrition enhancer comprises the following components in parts by weight: 60-80 parts of compound vitamins, 20-40 parts of compound minerals and 1-5 parts of lactose; the compound vitamin comprises the following components in percentage by weight: 0.55-0.85% of vitamin A, 0.4-0.5% of vitamin D, 3.5-4.8% of vitamin E, 3.00-4.00% of vitamin K 2 , 0.10-0.15% of vitamin B 1 , 1.00-1.50% of vitamin B 2 , 3.00-3.80% of vitamin B 6 , 0.05-0.15% of 6S-5-methyltetrahydrofolate calcium, 0.02-0.08% of vitamin B 12 , 19.00-22.00% of vitamin C, 20.10-28.50% of choline, 4.00-5.50% of L-carnitine, 4.20-5.50% of taurine and the balance lactose; the compound mineral comprises the following components in percentage by weight: 15.00-25.00% of ferrous gluconate, 6.50-8.70% of zinc gluconate, 0.75-1.25% of sodium selenite and the balance of lactose.
2. The maternal formula for promoting digestion comfort and stabilizing blood sugar according to claim 1, which is characterized by comprising the following raw material components in parts by weight: 60-80 parts of A2 type skim milk, 2-3.5 parts of galacto-oligosaccharide, 2-5.5 parts of fructo-oligosaccharide, 0.2-0.5 part of phospholipid, 0.6-0.9 part of compound nutrition enhancer, 0.8-1.5 parts of docosahexaenoic acid grease powder, 0.05-0.18 part of N-acetylneuraminic acid and 0.05-0.06 part of compound probiotic powder.
3. The maternal formula for promoting digestion comfort and stabilizing blood sugar according to claim 1, which is characterized by comprising the following raw material components in parts by weight: 65-80 parts of A2 type skim milk, 2.5-3.5 parts of galacto-oligosaccharides, 3-5.5 parts of fructo-oligosaccharides, 0.3-0.5 part of phospholipids, 0.7-0.9 part of compound nutrition enhancers, 0.8-1.2 parts of docosahexaenoic acid grease powder, 0.05-0.18 part of N-acetylneuraminic acid and 0.05-0.06 part of compound probiotics powder based on dry matter.
4. The pregnant and lying-in woman formula milk powder for promoting digestion comfort and stabilizing blood sugar according to claim 1, wherein the composite probiotic powder is composed of at least two of bifidobacterium animalis subspecies Bb-12, bifidobacterium animalis subspecies HN019, bifidobacterium animalis subspecies Bi-07 and bifidobacterium longum subspecies Bb536 in any ratio.
5. A method for preparing maternal formula milk powder for promoting digestion comfort and stabilizing blood glucose according to any one of claims 1-4, characterized by comprising the following steps:
step one, screening and collecting A2 raw cow milk:
selecting pure breed A2 dairy cows and carrying out clustered breeding and cultivation and collecting A2 raw dairy cows by carrying out gene identification screening on large-scale pasture dairy cows;
Step two, degreasing the raw milk of the A2:
filtering, cooling and storing the A2 raw milk obtained in the step one, degreasing to obtain skimmed milk, homogenizing the skimmed milk after degerming and separating, and then pasteurizing to obtain pasteurized milk, and cooling and storing;
Step three, batching:
Adding other auxiliary materials except the docosahexaenoic acid grease powder, the N-acetylneuraminic acid, the compound nutrition enhancer and the compound probiotic powder into a vacuum mixer according to the formula weight parts to be mixed; dissolving the compound nutrition enhancer according to the water-powder mass ratio required by the process at the dissolving temperature, adding the dissolved compound nutrition enhancer into a vacuum mixer, and mixing the dissolved compound nutrition enhancer with other auxiliary materials and pasteurized milk obtained in the step two to obtain the prepared milk;
step four, preparing a semi-finished product of milk powder:
homogenizing the prepared milk obtained in the step three, removing most of water in the prepared milk through vacuum sterilization and concentration to obtain concentrated milk, and performing spray drying and fluidized bed cooling on the obtained concentrated milk to obtain a milk powder semi-finished product;
Step five, preparing a milk powder finished product:
premixing the docosahexaenoic acid grease powder, the N-acetylneuraminic acid and the compound probiotic powder with part of the semi-finished milk powder obtained in the step four according to the formula requirement in parts by weight to obtain a premix, fully mixing the rest semi-finished milk powder with the premix, and packaging to obtain the finished pregnant and lying-in woman formula milk powder.
6. The method for preparing pregnant and parturient women's formula milk powder for promoting digestion comfort and stabilizing blood sugar according to claim 5, wherein the impurity degree of the A2 raw milk obtained by the filtering in the second step is less than 0.25ppm; step two, the pasteurization temperature is 80-85 ℃ and the sterilization time is 15s; in the third step, the mass ratio of water to powder is not lower than 8:1 when the compound nutrition enhancer is dissolved, and the dissolution temperature is 30-50 ℃.
7. The method for preparing pregnant and lying-in woman formula milk powder for promoting digestion comfort and stabilizing blood sugar according to claim 5 or 6, wherein in the fourth step, the homogenizing pressure is 160-210 bar, the sterilization temperature of vacuum sterilization and concentration is 85-98 ℃, the moisture of the prepared milk removed by concentration is 60%, and the density of the obtained concentrated milk is 1100-1200 kg/m 3; the pressure of the high-pressure pump for spray drying is 150-250 bar, the air inlet temperature is 160-200 ℃, the air exhaust temperature is 65-90 ℃, and the fluidized bed cooling is to cool the finished milk powder to 10-30 ℃; and fifthly, premixing for 5-10 min, wherein the mixing time is 5-10 min, the oxygen content in the package of the packaged bagged product is lower than 2.5%, and the oxygen content in the package of the canned product is lower than 5.0%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211429648.1A CN115708530B (en) | 2022-11-15 | 2022-11-15 | Pregnant and lying-in woman formula milk powder capable of promoting digestion comfort and stabilizing blood sugar and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211429648.1A CN115708530B (en) | 2022-11-15 | 2022-11-15 | Pregnant and lying-in woman formula milk powder capable of promoting digestion comfort and stabilizing blood sugar and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115708530A CN115708530A (en) | 2023-02-24 |
| CN115708530B true CN115708530B (en) | 2024-08-09 |
Family
ID=85233432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211429648.1A Active CN115708530B (en) | 2022-11-15 | 2022-11-15 | Pregnant and lying-in woman formula milk powder capable of promoting digestion comfort and stabilizing blood sugar and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115708530B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105407971A (en) * | 2013-05-31 | 2016-03-16 | 艾尔牛奶有限公司 | Beta-casein A2 and prevention of inflammation of the bowel |
| CN114304274A (en) * | 2021-11-23 | 2022-04-12 | 黑龙江爱维仕乳品有限公司 | Formula milk powder for pregnant and lying-in women at different stages and preparation method |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003503038A (en) * | 1999-06-29 | 2003-01-28 | ザ・ニュージーランド・ミルク・インスティチュート・リミテッド | Preventive supplements based on milk |
| CN103609748A (en) * | 2013-12-10 | 2014-03-05 | 内蒙古伊利实业集团股份有限公司 | Hypoglycaemic milk powder for pregnant women and preparation method thereof |
| NL2019906B1 (en) * | 2017-11-14 | 2019-05-20 | Ausnutria Hyproca B V | Composition comprising a2 b-casein and a vegetable fat mixture |
| CN110250288A (en) * | 2019-07-23 | 2019-09-20 | 宁波特壹食品有限公司 | Nursing period formula milk and preparation method thereof |
| CN110810515A (en) * | 2019-11-25 | 2020-02-21 | 海南国健高科技乳业有限公司 | Formula milk powder for pregnant and lying-in women and preparation method thereof |
| CN113068747A (en) * | 2020-03-24 | 2021-07-06 | 北京三元食品股份有限公司 | Pregnant and lying-in woman formula milk powder for promoting health of pregnant and lying-in women and infants |
| CN111602719A (en) * | 2020-05-11 | 2020-09-01 | 呼伦贝尔双娃乳业有限公司 | Organic formula milk powder for pregnant and lying-in women |
| CN113678897A (en) * | 2021-08-27 | 2021-11-23 | 庞海丰 | Formula milk powder for promoting nutrient absorption of pregnant and lying-in women and preparation method thereof |
-
2022
- 2022-11-15 CN CN202211429648.1A patent/CN115708530B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105407971A (en) * | 2013-05-31 | 2016-03-16 | 艾尔牛奶有限公司 | Beta-casein A2 and prevention of inflammation of the bowel |
| CN114304274A (en) * | 2021-11-23 | 2022-04-12 | 黑龙江爱维仕乳品有限公司 | Formula milk powder for pregnant and lying-in women at different stages and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115708530A (en) | 2023-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2605453T3 (en) | Maternal diet supplement | |
| RU2457836C2 (en) | Additive to maternal diet | |
| Sandström et al. | Effects of α-lactalbumin–enriched formula containing different concentrations of glycomacropeptide on infant nutrition | |
| US20050208035A1 (en) | Nutritional composition for treating an immune condition | |
| CN110754530A (en) | Formula milk powder capable of effectively promoting height development of children and production method thereof | |
| JP5864676B2 (en) | Composition for preventing or treating anemia | |
| CN104920618A (en) | Formula goat milk powder for pregnant and lying-in woman | |
| CN109169916A (en) | A kind of puerpera's nutriment and its production technology | |
| CN107912535A (en) | A kind of bovine colostrum composite powder and preparation method thereof | |
| CN111067104A (en) | Composite probiotic infant formula milk powder and preparation method thereof | |
| CN112106836A (en) | Yak milk powder for middle-aged and old people and preparation method thereof | |
| CN111587923A (en) | An infant formula containing sialic acid and its preparation method | |
| EA011075B1 (en) | Dry powdered milk formula | |
| CN107373487A (en) | A kind of ferrous bisglycinate chelate electuary | |
| CN115708530B (en) | Pregnant and lying-in woman formula milk powder capable of promoting digestion comfort and stabilizing blood sugar and preparation method thereof | |
| CN106418067A (en) | Health beverage capable of replenishing physical power and relieving fatigue | |
| EP2956015B1 (en) | Method for restoring and/or maintaining a positive net protein balance in a child | |
| CN113973923A (en) | Goat milk-based total nutrient formula powder for special medical purposes and preparation method thereof | |
| Committee on Nutrition | The use of whole cow's milk in infancy | |
| RU2341276C1 (en) | Method of gastrointestinal disturbance prevention in newborn calfs | |
| Hamed et al. | Overview of the Updates in Nutrient Profiles, Types, Indications and Side Effects of Infant Formula | |
| CN108935701A (en) | A kind of preparation method and application improving the goat milk powder of immunity, goat milk powder | |
| JP3247786B2 (en) | Foods Highly Containing β-Casein | |
| CN115702653A (en) | Sleep-assisting middle-aged and old-aged modified goat milk powder and preparation method thereof | |
| Atomei et al. | Nutrition in pregnancy–impact on anaemia in pregnant women |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |